NanoViricides Inc. (NNVC)

[changes_iv]

Fast tracked clinical trials, efficacy and safety, possible and soon!

Experts will be meeting this week at the World Health Organization (WHO) to discuss the role of new drugs and vaccines to help control the Ebola epidemic in West Africa. Last month, the WHO said that it is ethical to provide experimental drugs and vaccines for Ebola, but that there’s also a “moral duty” to conduct clinical trials of these experimental drugs and vaccines to determine whether they’re safe and effective. At the same time, a new study released last week shows that the Ebola virus is mutating rapidly, which could make it more transmissible or reduce the effectiveness of drugs and vaccines in the pipeline.

http://blogs.reuters.com/great-debate/2014/09/02/status-of-new-drugs-to-fight-mutating-ebola-virus/

A vaccine failure is when an organism develops a disease in spite of being vaccinated against it. Primary vaccine failure occurs when an organism's immune system does not produce enough antibodies when first vaccinated. Secondary vaccine failure occurs when enough antibodies are produced immediately after the vaccination, but the levels fall over time. While antibody levels always fall over time, this would be a more rapid loss of immunity than expected for that vaccine.

1. The vaccine virus may be a different serotype from the challenged virus.
2. Maternal antibody which protects neonates may interfere with vaccine presentation.
3. Some viruses notably Herpes Viruses are poorly neutralized and once established can spread between cells by fusion.
4. The vaccine virus may become denatured or inactivated during storage or administration.
5. The vaccine virus may be ineffective if it is manufactured incorrectly, for example containing insufficient antigen or live virus.
~ Wikipedia

More on vaccines and rare situations...

Get the measles vaccine, and you won’t get the measles—or give it to anyone else. Right? Well, not always. A person fully vaccinated against measles has contracted the disease and passed it on to others. The startling case study contradicts received wisdom about the vaccine and suggests that a recent swell of measles outbreaks in developed nations could mean more illnesses even among the vaccinated.

When it comes to the measles vaccine, two shots are better than one. Most people in the United States are initially vaccinated against the virus shortly after their first birthday and return for a booster shot as a toddler. Less than 1% of people who get both shots will contract the potentially lethal skin and respiratory infection. And even if a fully vaccinated person does become infected—a rare situation known as “vaccine failure”—they weren’t thought to be contagious.

http://news.sciencemag.org/health/2014/04/measles-outbreak-traced-fully-vaccinated-patient-first-time

Whooping cough outbreaks have occurred with increasing frequency in the last year and are beginning to become major news items, as highlighted by major outbreaks on-going in California. In virtually every article, the disease is described as “vaccine preventable” and blame is often cast upon Jenny McCarthy and autism-crazed parents that frequently refuse vaccination. But the facts of the matter are not that simple.

Despite the recent press on the vaccine-autism debate, infant vaccination rates remain at or near all-time highs with 96.2% of infants getting at least three doses of DTaP in 2008 versus just 61% getting at least three doses of DTP in 1991 [1]. Furthermore, in recent outbreaks, a majority of affected have in fact been completely vaccinated (see NJ outbreak in which ALL affected children had been completely vaccinated). So given that the most at-risk population (children under 3 months) is not eligible for vaccination and their protection depends on the protection of older children, the real question to emerge from the recent pertussis outbreaks should be “Why is the pertussis vaccine no longer as effective or as long lasting as it once was?” People and public health agencies should be DEMANDING the answer to this question. They instead seem content with the possible addition of another booster of the DTaP to be given at seven years of age, thus increasing the number of doses of DTaP now given to American children to 6 and unnecessarily boosting tetanus and diphtheria in the bargain.

http://www.smartvax.com/index.php?option=com_content&view=article&id=112:pertussis-vaccine-failure-should-be-a-wake-up-call
From NanoBusiness Alliance Interview with Dr. Anil R. Diwan, President of NanoViricides, Inc.,...

...vaccines usually fail with the emergence of mutated viruses. And when a person develops a disease, we still need to have a treatment

read more: http://www.internano.org/content/view/541/292/

Do we have a partner? Is that partner the USAMRIID or other?

All we do is make the drug. The partners do the testing.

We will announce a partnership agreement when everything is signed.

There are very few BSL4 facilities in the world with whom we can work

I think that we explained in the PR why we feel that we can dramatically improve the efficacy with our new improved techniques.

We need a partner to try to get a piece of the available $100M EHO (sic WHO) grant.

This WILL NOT delay the start of the tox studies.

Sent from my iPhone

Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
[e-mail]
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange

Once we test EbolaCide for efficacy and are successful, we should not be denied. The next step will be a fast track to WHO clinical trials to test for efficacy (again?) and safety!

I Need Help!, what say you?

There will always be a need and demand for vaccines, but many people won’t use them. We know this from experience. However, the existence of a nanoviricide treatment for a virus-borne illness means that treatment can begin after symptoms for influenza or some other virus-borne disease appear.

Based on animal studies, we believe that virus populations will be so reduced that symptoms would disappear in only a few hours. Immunity, however, would develop in the normal 21-day period so that the patient could not get the same infection again.

Some viruses—notably hepatitis, HIV, and herpes—might not be cleared entirely from the system because they hide inside various tissues. I believe, however, that symptoms will disappear, and the patient would not be contagious. When the virus emerges, however, it will encounter nanoviricides if they are in the patient’s system. Over time, there is a strong possibility that each reemergence will be smaller than the last, until the disease is gone.

http://www.mauldineconomics.com/download/transformational-wealth-from-three-tiny-companies

==============================================

"You can fool all of the people some of the time, and some of the people all of the time, but you can not fool all of the people all of the time." ~ Abraham Lincoln